ATHA | Athira Pharma, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.5200 - 0.5760
52 Week Range	0.4120 - 4.30
Beta	2.86
Implied Volatility	326.48%
IV Rank	59.90%
Day's Volume	221,716
Average Volume	4,796,433
Shares Outstanding	38,669,100
Market Cap	22,273,402
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-09-18

Valuation
Profitability
Growth
Health
P/E Ratio	-0.20
Forward P/E Ratio	N/A
EPS	-2.84
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	65
Country	USA
Website	ATHA

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

ATHA's peers: ABEO, ACAD, ALT, CTMX, SPRO, NLTX, TIL, NXTC, ASMB, ACHL, NUVB, FBIO, RVPH

*Chart delayed

Analyzing fundamentals for ATHA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ATHA Fundamentals page.

Watching at ATHA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ATHA Technicals page.